Drug-Coated Balloon Cuts TLR in Femoropopliteal Artery Disease

Share this content:
Drug-Coated Balloon Cuts TLR in Femoropopliteal Artery Disease
Drug-Coated Balloon Cuts TLR in Femoropopliteal Artery Disease

MONDAY, Aug. 22, 2016 (HealthDay News) -- For femoropopliteal artery disease, use of drug-coated balloon (DCB) is associated with reduced risk of target lesion revascularization (TLR) compared with conventional plain balloon (PB), with no effect of all-cause mortality, according to a review published in the August 22 issue of JACC: Cardiovascular Interventions.

Daniele Giacoppo, M.D., from the Technische Universität München in Germany, and colleagues identified eight randomized trials comparing DCB with PB for the treatment of femoropopliteal artery disease. They examined the risk of TLR and all-cause death with DCB and PB.

The researchers found that, compared with PB, DCB correlated with a marked 12-month TLR risk reduction (risk ratio [RR], 0.33; 95 percent confidence interval [CI], 0.19 to 0.57). The groups had a comparable risk of death (RR, 0.96; 95 percent CI, 0.47 to 1.95). In long-term outcomes assessment, the incidence of TLR was reduced with DCB (RR, 0.35; 95 percent CI, 0.24 to 0.51), while incidence of all-cause death was similar (incidence RR, 1.13; 95 percent CI, 0.60 to 2.15). There was significant heterogeneity present, with differential efficacy observed across devices. The available evidence was sufficient to prove superior antirestenotic efficacy for DCB over PB.

"Future trials investigating DCB angioplasty should include potentially more effective comparator therapies," the authors write.

One author disclosed financial ties to the medical device industry; one author disclosed patent applications in relation to drug-eluting stent technology.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »